Changchun High-Tech: Leuprorelin Mesylate Injection Approved, Specification 42mg

Changchun High-Tech announced that the company previously disclosed that GenSci Pharma obtained rights related to Leuprorelin Mesylate Injection. Recently, GenSci Pharma received the Drug Registration Certificate approved and issued by the National Medical Products Administration. The overseas-manufactured drug registration and marketing authorization application has been approved, with the approved indication being prostate cancer requiring androgen deprivation therapy, specification 42mg, and drug approval number Guoyaozhunzi HJ20260087.